AR050954A1 - Procedimiento para preparar compuestos de pirazolilo biciclicos - Google Patents

Procedimiento para preparar compuestos de pirazolilo biciclicos

Info

Publication number
AR050954A1
AR050954A1 ARP050104017A ARP050104017A AR050954A1 AR 050954 A1 AR050954 A1 AR 050954A1 AR P050104017 A ARP050104017 A AR P050104017A AR P050104017 A ARP050104017 A AR P050104017A AR 050954 A1 AR050954 A1 AR 050954A1
Authority
AR
Argentina
Prior art keywords
compound
formula
hydroxy
group
defined above
Prior art date
Application number
ARP050104017A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR050954A1 publication Critical patent/AR050954A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos han mostrado actuar como ligandos del receptor de cannabinoides y son por lo tanto utiles en el tratamiento de enfermedades asociadas a la mediacion de los receptores de cannabinoides en animales. Reivindicacion 1: Un procedimiento para preparar un compuesto que tiene la formula (1), en la que: R0a, R0b, R1b, y R1c son cada uno independientemente halo, alcoxi C1-4, alquilo C1-4, alquilo C1-4 halosustituido, o ciano; n y m son cada uno independientemente 0, 1 o 2; y R4 es un resto químico seleccionado del grupo que consta de alquilo C1-8, arilo, heteroarilo, arilalquilo C1-4, anillo(s) carbocíclico(s) parcial o totalmente saturado(s) de 3 a 8 miembros, heteroarilalquilo C1-3, lactona de 5 a 6 miembros, lactama de 5 a 6 miembros, y un heterociclo parcial o totalmente saturado de 3 a 8 miembros, donde dicho resto químico está sustituido opcionalmente con uno o más sustituyentes; una sal farmacéuticamente aceptable del mismo, o un solvato o hidrato de dicho compuesto o de dicha sal; que comprende las etapas de: a) proteger el grupo hidroxi de un compuesto de formula (2) con un grupo protector de hidroxi para formar un compuesto hidroxi-protegido de formula (2), en las que R0a, R0b, R1b, R1c, n y m son como se definen anteriormente, y Pg es un grupo protector de hidroxi; b) hacer reaccionar el compuesto hidroxi protegido de formula (2) con un compuesto de formula (3) para formar un compuesto de formula (4), en las que R0a, R0b, R1b, R1c, n, m Pg, y R4 son como se definen anteriormente; c) convertir el grupo hidroxi de dicho compuesto de formula (4) en un grupo saliente para producir un compuesto de formula (5), en las que R0a, R0b, R1b, R1c, m, n Pg, y R4 son como se definen anteriormente y L es un grupo saliente; d) eliminar dicho grupo protector de hidroxi y ciclar dicho compuesto de formula (5) para formar el compuesto de formula (1); y e) aislar dicho compuesto de formula (1), o una sal farmacéuticamente aceptable del mismo, o un solvato o hidrato de dicho compuesto o de dicha sal.
ARP050104017A 2004-09-27 2005-09-26 Procedimiento para preparar compuestos de pirazolilo biciclicos AR050954A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61361304P 2004-09-27 2004-09-27

Publications (1)

Publication Number Publication Date
AR050954A1 true AR050954A1 (es) 2006-12-06

Family

ID=36010942

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104017A AR050954A1 (es) 2004-09-27 2005-09-26 Procedimiento para preparar compuestos de pirazolilo biciclicos

Country Status (16)

Country Link
US (1) US20070260056A1 (es)
EP (1) EP1797041A2 (es)
JP (1) JP2008514584A (es)
KR (1) KR20070051921A (es)
CN (1) CN101027285A (es)
AR (1) AR050954A1 (es)
AU (1) AU2005288671A1 (es)
BR (1) BRPI0515281A (es)
CA (1) CA2581747A1 (es)
IL (1) IL181721A0 (es)
MX (1) MX2007003586A (es)
NO (1) NO20070790L (es)
NZ (1) NZ553071A (es)
TW (1) TW200626557A (es)
WO (1) WO2006035310A2 (es)
ZA (1) ZA200701279B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
EP1951678A1 (en) * 2005-10-21 2008-08-06 Mitsubishi Tanabe Pharma Corporation Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653304B2 (en) * 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2457922A1 (en) * 2001-08-31 2003-03-13 University Of Connecticut Novel pyrazole analogs acting on cannabinoid receptors
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Also Published As

Publication number Publication date
WO2006035310A2 (en) 2006-04-06
KR20070051921A (ko) 2007-05-18
WO2006035310A3 (en) 2006-06-01
JP2008514584A (ja) 2008-05-08
CN101027285A (zh) 2007-08-29
TW200626557A (en) 2006-08-01
MX2007003586A (es) 2007-05-21
IL181721A0 (en) 2007-07-04
BRPI0515281A (pt) 2008-07-15
NO20070790L (no) 2007-03-08
ZA200701279B (en) 2008-09-25
AU2005288671A1 (en) 2006-04-06
CA2581747A1 (en) 2006-04-06
US20070260056A1 (en) 2007-11-08
NZ553071A (en) 2009-07-31
EP1797041A2 (en) 2007-06-20

Similar Documents

Publication Publication Date Title
AR044038A1 (es) Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
AR044037A1 (es) Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
AR044036A1 (es) Compuestos de pirazolopirimidinas y pirazolopiridinas como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos
AR048669A1 (es) Derivados biciclicos de bisamida
NO20055688L (no) Organiske forbindelser
ECSP066858A (es) Inhibidores de gsk-3
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
PE20130229A1 (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer
HK1111999A1 (en) Spiroketal derivative and use thereof as diabetic medicine
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
AR082499A1 (es) Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos
AR057954A1 (es) Compuestos derivados de acido tartarico, composiciones farmaceuticas que los contienen y usos como agentes antimicrobianos.
ES2670878T3 (es) Cianometilpirazol carboxamidas como inhibidores de la Janus quinasa
AR046831A1 (es) Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR067896A1 (es) Procedimiento para sintetizar compuestos utiles para tratar hepatitis c
CO6280476A2 (es) Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina
AR067991A1 (es) Pirrolidina-aril-eteres como antagonistas de receptores de nk3
AR053342A1 (es) Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
AR074817A1 (es) Dihidropiridona-amidas como moduladores de p2x7
AR047958A1 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
DE602004020730D1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
AR056418A1 (es) Derivados de bencimidazol como 5-ht6, 5-ht2a, metodo para la obtencion del compuesto y el uso para la fabricacion de un mediicamento

Legal Events

Date Code Title Description
FB Suspension of granting procedure